(RTTNews) -  AstraZeneca Plc (AZN: News ) said a new analysis of 6,801 women in the JUPITER study showed Crestor 20 mg significantly reduced cardiovascular events by nearly half in women without cardiovascular disease. This analysis also showed a 42% reduction in CV events for men.

JUPITER or Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin study was a long-term, large-scale study of 17,802 patients designed to determine if rosuvastatin 20 mg decreases the risk of myocardial infarction, stroke and other cardiovascular events.

In JUPITER, 6,801 women aged 60 and over were randomized to rosuvastatin or placebo. Consistent with the data seen for men, risk reductions among women were observed for all components of the primary endpoint.
AstraZeneca said that it filed a regulatory submission including the JUPITER data in the first half of 2009 and if approved, will begin promotional activities within the approved labeling.

Click here to receive FREE breaking news email alerts for AstraZeneca PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com